Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2
Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Lisset Hermida(Centro de Ingeniería Genética y Biotecnología), Vivian Huerta(Centro de Ingeniería Genética y Biotecnología), Edith Suzarte(Centro de Ingeniería Genética y Biotecnología), Yasser Perera(Construction Development (Qatar)), Panchao Ai(Zhejiang Yongning Pharma (China)), Gerardo Guillén(Hunan City University), Liz Alvarez‐Lajonchere(Centro de Ingeniería Genética y Biotecnología), Jiang Zaixue(Dongguan People’s Hospital), Ricardo Silva(Centro de Ingeniería Genética y Biotecnología), Rong Chen(Zhongda Hospital Southeast University), Alexis Musacchio(Instituto Cajal), Ke Yang(Northwestern Polytechnical University), Yang Liling(Dongguan People’s Hospital), Changyuan Tan(Zhejiang Yongning Pharma (China))
Cited by 1
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139